CSI Market
Sign In | Register

Oramed Pharmaceuticals Inc (ORMP) Annual Cash Flow Statement

Annual · GAAP · USD millions
Access ORMP quarterly Cash Flow →
Cash flow data covering Oramed Pharmaceuticals Inc–Aug 31 2021 offers a view into how Dec 31 2025's cash position has developed alongside business activity.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Annual Report, GAAP in USD millions
ITEM 		(Dec 31 2025)
12 Months 		(Dec 31 2024) (Dec 31 2023) (Dec 31 2021) (Aug 31 2021)
Operating Activities
Income190.86
Depreciation & amortization0.12
Amortization of Other Assets0.00
Increase (Decrease) in Deferred Revenue0.00
Restructuring & Impairment Charges0.00
Provision For Loan Losses Expensed0.00
Inventories Decrease /-Increase0.00
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Assets, Total0.00
Share-based Compensation11.14
Income (Loss) from Equity Method Investments0.00
Fair Value Adjustment of Warrants6.24
Issuance Of Stock And Warrants To Be Issued For Services Or Claims-
Imputed Interest Expense-
Other Than Temporary Impairment Losses Investments Portion Recognized In Earnings Net Availableforsale Securities-
Warrants Exchanged-
Increase Decrease In Prepaid Expenses Other Current Assets And Related Parties Current-
Exchange Of Warrants-
Noncash Merger Related Costs-
Noncash Expense For Acquired Inprocess Research And Development-
Changes At Fair Value Of Investments-
Gain On Amounts Funded In Respect Of Employee Rights Upon Retirement-0.01
Increase Decrease In Operating Lease Liability-2.70
Foreign Currency Transaction Gain Loss After Tax-
Income taxes7.91
Gain (Loss) on Investments0.00
Increase (Decrease) in Employee Related Liabilities0.01
Increase (Decrease) in Accounts Payable and Accrued Liabilities1.13
Increase (Decrease) in Pension and Postretirement Obligations0.00
Deferred Revenue and Customer Advances and Deposits0.00
Prepaid Expense and Other Assets-6.91
Other Working Capital-0.06
Other Noncash Income (Expense)0.00
Other net-0.03
Payments for (Proceeds from) Other Operating Activities0.00
Discontinued operations0.00
Net Cash flow from Operating Activities-9.15
Investing Activities
Capital Expenditures-0.01
Sale of Capital Items0.00
Proceeds from Sale and Maturity of Held-to-maturity Securities83.07
Payments to Acquire Marketable Securities-9.85
Real Estate Investments0.00
Payments To Acquire Funds In Respect Of Employee Rights Upon Retirement-
Funds In Respect Of Employee Rights Upon Retirement-
Payments To Acquire Mutual Funds-
Payments Of Corporate Bonds Designated As Fair Value-
Proceeds From Shortterm Deposits97.15
Proceeds From Investment At Fair Value0.01
Exercise Of Closing Penny Warrants And Subsequent Penny Warrants-
Investment In Equity Method Investee-
Lifeward Transactions-
Increase (Decrease) in Restricted Cash0.00
Payments to Acquire Loans Held-for-investment0.00
Payments for (Proceeds from) Deposits0.00
Proceeds from Sale of Other Investments-1.92
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Acquisition Net of Cash Acquired0.00
Interest in Subsidiaries and Affiliates-0.75
Sale of businesses0.00
Accounts payable0.00
Receivables-3.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities5.44
Financing Activities
Short-term debt Net-0.50
Other borrowing transactions0.00
Long-term debt - borrowings0.00
Long-term debt - repayments0.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock-4.74
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net0.00
Proceeds From Receipts On Account Of Shares Issuances-
Proceeds From Stock Options And Warrants Exercised-
Proceeds From Exercise Of Warrants And Options-
Interest Received7.38
E F F E C T O F E X C H A N G E R A T E C H A N G E S O N C A S H-
Proceeds From Issuance Of Common Stock And Warrants-
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents9.06
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities-4.74
Effect of exchange rate on cash flow0.00
Discontinued operations0.00
Free Cash Flow-9.15
Total Cash Flow-8.47
4 historic quarters locked

Sign in to unlock the full Oramed Pharmaceuticals Inc cash flow history.

Sign In Create Free Account

About Oramed Pharmaceuticals Inc Annual Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-K filings and normalized by CSIMarket.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001213900-26-034835

Figures are derived from filed reports and may be restated. Historical data is subject to revision.

Untitled Document 





                    


    



  Get the full CSIMarket dataset:
  Subscribe
  API
  License